PAS
CBIO

Point72 Asia (Singapore)’s Crescent Biopharma CBIO Stock Holding History

Point72 Asia (Singapore)’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-519
Closed -$156K – 1201
2024
Q1 		$156K Buy
+519
New +$155K 0.04% 516

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asia (Singapore)'s CBIO Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 519 shares — an estimated $156K sold.

Point72 Asia (Singapore) first reported a position in CBIO in Q1 2024 and held it in 1 quarter. The position peaked at $156K in Q1 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 519 Crescent Biopharma shares in Q2 2024, an estimated $156K.
  • Point72 Asia (Singapore) first reported a position in Crescent Biopharma in Q1 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Crescent Biopharma position peaked at $156K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.